The US FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

A recovering ketamine addict from Portsmouth warns of the drug's dangers as use soars among young people. The number treated across the region was an increase on the previous year. The early ...

The FDA approved an oral combination of meloxicam and rizatriptan (Symbravo) to treat adults with acute migraine with or without aura, Axsome Therapeutics announced.

A new migraine medication, meloxicam and rizatriptan (Symbravo), was just approved by the U.S. Food and Drug Administration (FDA) that may bring relief to people who haven’t had good results ...

The novel formulation of rizatriptan and meloxicam (Symbravo, Axome Therapeutics) is for the acute treatment of migraine with ...

Axsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo (meloxicam and rizatriptan ... diversifies Axsome’s commercial drug portfolio. The company currently markets Auvelity ...

but it did not divulge the drug's price. Formerly known as AXS-07, Symbravo is a combination treatment of meloxicam and rizatriptan. Meloxicam is a nonsteroidal, anti-inflammatory molecule ...

The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.